论文部分内容阅读
当前,抗病毒治疗是慢性乙肝的根本治疗方法,已成为共识。很多研究结果显示,持续的高水平的乙肝病毒复制,是慢性乙肝患者发展成为肝硬化和肝癌的高危因素,而有效的抗病毒治疗可减少肝硬化和肝癌的发生率。目前,国内外公认的抗乙肝病毒治疗药物主要包括有干扰素和核苷类药物两大类,而核苷类药物以其服用简便、抗病毒能力强而被广泛的使用,在现有的四种核苷类似物中,广大的乙肝患者应该如何选择呢?为此,本刊特邀华中科技大学同济医学院附属同济医院的田德英教授,就慢性乙肝抗病毒的药物选择问题给予详细解答。
Currently, antiviral therapy is the fundamental treatment of chronic hepatitis B has become the consensus. Many studies show that sustained high levels of hepatitis B virus replication are risk factors for the development of cirrhosis and HCC in patients with chronic hepatitis B. Effective antiviral therapy can reduce the incidence of cirrhosis and HCC. At present, the domestic and international recognized anti-hepatitis B virus drugs mainly include two major classes of interferon and nucleoside drugs, while the nucleoside drugs are widely used by their ease of use and strong antiviral ability. In the existing four Among the nucleoside analogues, how to choose the majority of patients with hepatitis B? To this end, we invited Professor Tian Deying from Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology to give a detailed answer to the question about drug selection of chronic hepatitis B virus.